Who are hydrochlorothiazide, losartan's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BERLIM 25/10 association, BERLIM 25/20 ASSOCIATION, Losartan + hydrochlorothiazide in fixed dose.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hydrochlorothiazide-losartan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

hydrochlorothiazide, losartan — Competitive Intelligence Brief

hydrochlorothiazide, losartan (hydrochlorothiazide, losartan) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor antagonist + thiazide diuretic combination. Area: Cardiovascular.

marketed Angiotensin II receptor antagonist + thiazide diuretic combination AT1 receptor (losartan); sodium-chloride cotransporter (hydrochlorothiazide) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

hydrochlorothiazide, losartan (hydrochlorothiazide, losartan) — University Hospital, Strasbourg, France. This combination reduces blood pressure by blocking angiotensin II receptors (losartan) and increasing urinary sodium and water excretion (hydrochlorothiazide).

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
hydrochlorothiazide, losartan TARGET	hydrochlorothiazide, losartan	University Hospital, Strasbourg, France	marketed	Angiotensin II receptor antagonist + thiazide diuretic combination	AT1 receptor (losartan); sodium-chloride cotransporter (hydrochlorothiazide)
BERLIM 25/10 association	BERLIM 25/10 association	EMS	phase 3	Angiotensin II receptor antagonist + thiazide diuretic combination	AT1 receptor (angiotensin II type 1 receptor); thiazide-sensitive sodium-chloride cotransporter
BERLIM 25/20 ASSOCIATION	BERLIM 25/20 ASSOCIATION	EMS	phase 3	Angiotensin II receptor antagonist + thiazide diuretic combination	AT1 receptor (angiotensin II type 1 receptor); thiazide-sensitive sodium-chloride cotransporter
Losartan + hydrochlorothiazide in fixed dose	Losartan + hydrochlorothiazide in fixed dose	Laboratorios Silanes S.A. de C.V.	phase 3	Angiotensin II receptor antagonist + thiazide diuretic combination	AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor antagonist + thiazide diuretic combination class)

EMS · 2 drugs in this class
Laboratorios Silanes S.A. de C.V. · 1 drug in this class
University Hospital, Strasbourg, France · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). hydrochlorothiazide, losartan — Competitive Intelligence Brief. https://druglandscape.com/ci/hydrochlorothiazide-losartan. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab